IGPA meeting: Costs to be central to biosimilars' success
This article was originally published in SRA
Executive Summary
While the lack of clarity in biosimilars legislation in the US may be causing much gnashing of industry teeth1, the lingering uncertainty, in fact, does not really matter that much. That is because the first big losses of exclusivity for blockbuster biologics in this market will not happen for a few years yet.